Oncotelic raises $358.5K via secured convertible note with Mast Hill Fund

Oncotelic Therapeutics, Inc.

Issued $398,333.33 convertible promissory note (10% OID, 10% interest, 1-year maturity) to Mast Hill Fund for net proceeds of ~$350K after fees.
Note convertible at $0.07/share; also issued 1,422,613 warrants at $0.15/share and 1,600,446 commitment shares.
Note secured against company assets excluding certain JV assets (OT-101, CA4P, Oxi4503, AI technologies).
Proceeds designated for general working capital; prepayment allowed with 3 trading days' notice.
Shares issuable upon conversion/exercise not registered; registration rights agreement filed.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Oncotelic Therapeutics, Inc. incurred convertible notes of $398,333.33 with Mast Hill Fund, LP at 10% per annum maturing the earlier of (a) the one-year anniversary of the date of the 2026 Mast Hill Purchase Agreement, or (b) the acceleration of the maturity...upon occurrence of a.

Instrument: convertible notes
Principal: $398,333.33
Counterparty: Mast Hill Fund, LP
Rate: 10% per annum
Maturity: the earlier of (a) the one-year anniversary of the date of the 2026 Mast Hill Purchase Agreement, or (b) the acceleration of the maturity...upon occurrence of a
Event: incurrence

Exact text from the filing

On January 23, 2026, Oncotelic Therapeutics, Inc. (the "Company" or "Our") entered into a Securities Purchase Agreement (the "2026 Mast Hill Purchase Agreement "), with Mast Hill Fund, LP (" Mast Hill "), and the Company issued a convertible promissory note in the aggregate gross principal amount of $398,333.33 (the " 2026 Mast Hill Note ").

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Oncotelic Therapeutics, Inc. entered into 2026 Mast Hill Purchase Agreement with Mast Hill Fund, LP valued at $398,333.33 (effective 2026-01-23).

Action: entry
Agreement: equity purchase
Counterparty: Mast Hill Fund, LP
Value: $398,333.33
Effective: 2026-01-23

Exact text from the filing

On January 23, 2026, Oncotelic Therapeutics, Inc. (the “Company” or “Our”) entered into a Securities Purchase Agreement (the “2026 Mast Hill Purchase Agreement ”), with Mast Hill Fund, LP (“ Mast Hill ”), and the Company issued a convertible promissory note in the aggregate gross principal amount of $398,333.33 (the “ 2026 Mast Hill Note ”).

View on SEC.gov

306 debt financings filed in the last 30 days. Browse all debt financings →

Oncotelic Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-004237

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.